GlassScriptPhysician profile
Allison Lea Galloway
NPI 1811143944
$1,465.82
in general payments reported to CMS, 2019-2025
22 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.86 · 2021: $11.14 · 2022: $44.02 · 2023: $190 · 2024: $1,092 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Long Term Medical Supply Or Device Loan: $49.95 · Gift: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.35 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Gift | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $170.07 | 2023-2024 | Repatha, Evenity, Prolia |
| Beta Bionics, INC. | $168.66 | 2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $162.40 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $119.21 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $101.32 | 2023-2024 | Mounjaro, Jardiance, Baqsimi |
| Radius Health, INC. | $96.90 | 2024-2025 | Tymlos |
| Abbott Laboratories | $80.83 | 2024-2025 | Freestyle Insulinx, Freestyle Libre |
| Medtronic, INC. | $76.56 | 2023-2024 | Minimed 780g |
| Insulet Corporation | $75.22 | 2022-2024 | Omnipod |
| Abbvie INC. | $57.35 | 2023-2025 | |
| Chiesi USA, INC. | $54.89 | 2024 | Mycapssa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.35 | 2023-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $42.62 | 2023-2024 | |
| Mannkind Corporation | $42.50 | 2024 | |
| Almatica Pharma LLC | $36.98 | 2024 | Teriparatide |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $31.50 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $23.63 | 2024 | Gvoke Hypopen |
| Corcept Therapeutics | $18.28 | 2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $16.64 | 2022 | |
| Pfizer INC. | $15.03 | 2024 | |
| Biomarin Pharmaceutical INC. | $15.02 | 2024 | Voxzogo 1.2mg |
| Horizon Therapeutics Plc | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.